Myriad Genetics, Inc. (
30th Annual J.P. Morgan Healthcare Conference
January 11, 2012 4:30 p.m. ET
Peter Meldrum - President and Chief Executive Officer
My apologies to cut the lunch time speaker but let me introduce or next company here, it’s Myriad. For those interested in the breakout, it’s going to be across the hallway in the Georgian Room, and let me introduce Pete Meldrum to tell you a little bit more about the story. Pete?
Thank you, and welcome to the Myriad Genetics presentation. Before I begin I would like to point out that I may be making some forward-looking statements, please refer to our SEC filings for risk factors that may cause those statements to differ materially from actual events. Myriad Genetics is the leader in the development and marketing of transforming molecular diagnostic products. Products that assess an individual’s risk for developing cancer later in life, products that help manage specifically to the individual based on their individual genetic makeup, their disease more efficiently. Products that save lives and improve the quality of life.
Myriad has launched nine commercial products to date and we have a strong pipeline of 13 additional products that the company is diligently working on. These products are marketed through our own sales force which consists of 350 individuals throughout the United States, and just recently we have opened our labs in the Europe as we begin to expand internationally. And our products are covered by a strong intellectual property state of 182 issued patents.